Cerevel Net Tangible Assets vs Deferred Long Term Liab Analysis
CERE Stock | USD 41.00 0.33 0.80% |
Cerevel Therapeutics financial indicator trend analysis is way more than just evaluating Cerevel Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cerevel Therapeutics is a good investment. Please check the relationship between Cerevel Therapeutics Net Tangible Assets and its Deferred Long Term Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cerevel Therapeutics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Net Tangible Assets vs Deferred Long Term Liab
Net Tangible Assets vs Deferred Long Term Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cerevel Therapeutics Net Tangible Assets account and Deferred Long Term Liab. At this time, the significance of the direction appears to have pay attention.
The correlation between Cerevel Therapeutics' Net Tangible Assets and Deferred Long Term Liab is -0.95. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of Cerevel Therapeutics Holdings, assuming nothing else is changed. The correlation between historical values of Cerevel Therapeutics' Net Tangible Assets and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Cerevel Therapeutics Holdings are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Net Tangible Assets i.e., Cerevel Therapeutics' Net Tangible Assets and Deferred Long Term Liab go up and down completely randomly.
Correlation Coefficient | -0.95 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Most indicators from Cerevel Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cerevel Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cerevel Therapeutics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. At present, Cerevel Therapeutics' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 523.9 M, whereas Enterprise Value Over EBITDA is forecasted to decline to (15.12).
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 220.1M | 367.8M | 441.6M | 463.7M | Cost Of Revenue | 2.7M | 4.9M | 5.6M | 4.2M |
Cerevel Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Cerevel Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cerevel Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Current Liabilities | 14.9M | 29.5M | 42.5M | 72.6M | 92.2M | 96.8M | |
Retained Earnings | (244.3M) | (390.9M) | (616.2M) | (967.8M) | (1.4B) | (1.3B) | |
Accounts Payable | 2.1M | 5.0M | 11.3M | 10.1M | 11.9M | 6.6M | |
Common Stock Shares Outstanding | 127.1M | 73.6M | 136.6M | 151.3B | 162.1M | 154.0M | |
Other Current Assets | 69K | 6.9M | 12.3M | 13.6M | 10.7M | 11.2M | |
Total Current Assets | 87.1M | 390.6M | (117.8M) | 905.7M | 1.0B | 1.1B | |
Net Tangible Assets | 77.8M | 384.5M | 578.7M | 521.2M | 599.4M | 326.7M | |
Other Assets | 6.2M | 6.1M | 0.0 | 4.8M | 4.3M | 4.6M | |
Property Plant Equipment | 27.5M | 48.6M | 51.7M | 27.5M | 31.6M | 34.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cerevel Therapeutics is a strong investment it is important to analyze Cerevel Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cerevel Therapeutics' future performance. For an informed investment choice regarding Cerevel Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cerevel Therapeutics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Cerevel Stock analysis
When running Cerevel Therapeutics' price analysis, check to measure Cerevel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cerevel Therapeutics is operating at the current time. Most of Cerevel Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cerevel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cerevel Therapeutics' price. Additionally, you may evaluate how the addition of Cerevel Therapeutics to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Cerevel Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cerevel Therapeutics. If investors know Cerevel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cerevel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.73) | Return On Assets (0.30) | Return On Equity (0.92) |
The market value of Cerevel Therapeutics is measured differently than its book value, which is the value of Cerevel that is recorded on the company's balance sheet. Investors also form their own opinion of Cerevel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cerevel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cerevel Therapeutics' market value can be influenced by many factors that don't directly affect Cerevel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cerevel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cerevel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cerevel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.